Lilly Bets $3.8B on Psychedelics; UNH Crushes Q2

Eli Lilly ($LLY) announced the acquisition of AtaiBeckley for up to $3.8 billion, marking a significant expansion into psychedelic-based therapies for hard-to-treat depression. The deal structure includes $2.8 billion upfront at $6.75 per share in cash, plus up to $1 billion in milestone payments. The acquisition brings $LLY a late-stage psychedelic nasal spray, though pivotal trial data will not arrive until 2029. The transaction reflects broader Big Pharma confidence in neuroscience and psychiatric pharmaceuticals, with $LLY's immunology, oncology, and neuroscience medicines collectively growing 160% last quarter. The deal is positioned to strengthen the company's neuroscience growth strategy as traditional franchises face evolving competitive dynamics.

UnitedHealth Group ($UNH) posted Q2 2026 adjusted earnings per share of $6.38, up 56% from a weak year-earlier result and 30% ahead of the $4.91 consensus forecast. The earnings beat was driven by lower-than-expected benefit costs, sending the stock surging past a buy point initially, though the breakout later faltered. Rival managed-care providers including Humana, Centene, and Elevance Health gained on the warm initial reception to $UNH's results. The quarter demonstrated strong EPS growth amid cost pressures and strategic investments in AI. Global stock markets rose 13.8% in Q2, providing a supportive backdrop for the managed care sector's performance.

Abbott Laboratories ($ABT) reported Q2 2026 adjusted earnings of $1.31 per share, topping Wall Street's estimate of $1.28. The healthcare company raised its full-year profit guidance following the beat. The results demonstrated continued strength in $ABT's diversified medical device, diagnostics, and nutritional products portfolio. The earnings outperformance and raised outlook signal sustained demand across the company's product lines despite broader healthcare cost pressures affecting the managed care sector.

Merck ($MRK) saw analysts refine their models with bullish firms setting price targets in a $138 to $155 range, above a refreshed fair value estimate of $132.78 per share. The updated targets reflect revised earnings assumptions, views on the Q2 setup, and analysis of how the company's pipeline and regulatory backdrop could influence risk-reward dynamics. Pfizer ($PFE) shares were described as fairly priced following a 22% decline over the past five years, with recent approvals and oncology progress supporting expectations for future cash generation. Separately, Arbutus received approximately $178 million from Moderna as part of a patent litigation settlement announced on July 8. Prediction market Kalshi introduced contracts allowing users to bet on clinical trial outcomes and FDA drug approval decisions.

Investors will focus on upcoming earnings reports and pipeline developments across the sector. AbbVie ($ABBV) is expected to report Q2 results on July 31, with the neuroscience business anticipated to post solid growth driven by key brands and Vyalev. Amgen ($AMGN) has an impressive earnings surprise history and possesses the right combination of factors for a likely beat in its next quarterly report. The sector faces ongoing scrutiny around drug pricing policy, Medicare negotiations, and regulatory changes, though recent strong earnings from managed care and medical device companies suggest resilient fundamentals. Eli Lilly's psychedelic depression therapy acquisition will draw attention to neuroscience pipeline developments across Big Pharma, though pivotal data remains years away.